Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05742360

Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype

The primary objective of this study is to determine the longer-term (6 months) effect of CPAP therapy on change in 24-hour mean blood pressure (24hMBP) in OSA subjects with the excessively sleepy symptom subtype.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The Ohio State University - Martha Morehouse Medical Pavilion, Suite 2600, Columbus, Ohio, United States

Loading trial locations.

About this study

This is a prospective, non-randomized, observational, two-center study involving newly diagnosed subjects with moderate-severe OSA with the excessively sleepy symptom subtype.

Variables of Interest: Change in 24-hour ambulatory BP, change in sitting BP, change in reaction time by psychomotor vigilance test (PVT)

Participants will complete questionnaires that pertain to demographics, lifestyle factors, and co-morbidities. The blood samples will be used to determine levels of BP medications and serum creatinine. Measurements will be collected at baseline and at 6-month follow-up visits.

Data Analysis Approach: To correct for potential bias in the non-randomized comparison, the investigators will apply a Propensity Score (PS) Design via subclassification. Models to derive the PS values used in this design will include a number of covariates relevant to CPAP adherence, including age, sex, obesity (BMI, neck circumference, waist-to-hip ratio), current smoking, history of hypertension, diabetes mellitus (history, medications), lipid profile, hyperlipidemia (history, medications), family history of premature coronary disease, Charlson comorbidity index, physical activity (IPAQ), diet, OSA severity (AHI, ODI4, T90), sleepiness (Epworth Sleepiness Scale), educational attainment, socioeconomic status (postcode), insomnia symptoms (Insomnia Symptom Questionnaire), anxiety and depression-related symptoms (Patient Health Questionnaire-2), self-efficacy (General self-efficacy scale), and medication adherence (Medication Adherence Report Scale [MARS-5]). Baseline values of outcome measures will also be included in the PS model. After creating the PS design, all analyses are performed accounting for PS subclass as a categorical stratification factor. Evaluations of the CPAP effect on binary outcomes are performed utilizing conditional logistic regression. Similarly, CPAP effects in the context of survival analyses (e.g., Cox Proportional Hazards models) or on continuous outcomes (e.g., linear regression) are assessed by including PS subclass as a categorical covariate in all models.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-75 years
  • Moderate-severe OSA (defined as ODI ≥10 events/hour) via Polysomnography (PSG) or Home Sleep Apnea Study (HSAT) done based on clinical grounds
  • Excessively sleepy subtype determined by patient-reported symptoms
  • Willing to accept CPAP therapy
  • An elevated baseline office BP defined as ≥120 or ≥80 mmHg
  • Planned PAP (CPAP or bi-level PAP) treatment by treating provider

Exclusion criteria

  • Recent changes (within 3 months) to BP medications among those who are on these medications
  • Unable to apply ABPM cuff
  • Current use of CPAP or other OSA treatments
  • Resting, awake SaO2 <90% or use of home oxygen therapy
  • New York Heart Association (NYHA) categories III-IV of heart failure
  • Presence of Cheyne-Stokes Respiration (CSR) in sleep study identified by typical crescendo-decrescendo pattern of respiration with associated apneas and/or hypopneas in the absence of inspiratory flow limitation
  • Predominantly central sleep apnea (AHI≥15 events/hour, with >50% central events [apnea or hypopnea])
  • Life expectancy <2 years
  • Pregnancy
  • Clinical history of chronic kidney disease (Stage 5) requiring dialysis, or renal transplant
  • Systolic BP > 180 mmHg

Treatment and study plan

CPAP therapy

Device

CPAP treatment of obstructive sleep apnea with the excessively sleepy symptom subtype

Primary outcomes

  1. Change in 24-hour Mean Blood Pressure

    Time frame: Change from baseline 24-hour Mean Blood Pressure at 6-months after initiation of CPAP therapy

    24-hour Mean Blood Pressure obtained from ambulatory blood pressure monitoring (ABPM)

Secondary outcomes

  1. Nocturnal Mean BP

    Time frame: Change from baseline nocturnal Mean Blood Pressure at 6-months after initiation of CPAP therapy

    Nocturnal Mean Blood Pressure obtained from ambulatory blood pressure monitoring (ABPM)

  2. Reciprocal of Reaction Time

    Time frame: Change from baseline reaction time at 6-months after initiation of CPAP therapy

    Reciprocal of reaction time obtained by Psychomotor Vigilance Test

Sponsors and collaborators

Lead sponsor

Ohio State University

Other

Collaborators

  • University of Pennsylvania

Registry information

Official study title

Effect of CPAP on 24-Hour Blood Pressure in the Excessively Sleepy Obstructive Sleep Apnea Subtype

Important dates

Study start
2023
Primary completion
2027
Study completion
2028
First posted
Feb 24, 2023
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.